X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (307) 307
immunotherapy (276) 276
oncology (255) 255
immune-related adverse events (224) 224
nivolumab (222) 222
ipilimumab (182) 182
humans (159) 159
melanoma (159) 159
cancer (139) 139
pembrolizumab (131) 131
immunology (101) 101
care and treatment (100) 100
immune-related adverse event (94) 94
metastatic melanoma (93) 93
adverse events (91) 91
immune checkpoint inhibitors (87) 87
metastasis (84) 84
patients (82) 82
male (75) 75
lung cancer (71) 71
chemotherapy (68) 68
open-label (67) 67
female (66) 66
therapy (66) 66
advanced melanoma (65) 65
case report (64) 64
complications and side effects (64) 64
toxicity (64) 64
aged (63) 63
middle aged (62) 62
antibodies, monoclonal - adverse effects (61) 61
immune checkpoint inhibitor (61) 61
analysis (59) 59
docetaxel (57) 57
cell lung-cancer (56) 56
checkpoint inhibitors (55) 55
cancer therapies (52) 52
pd-1 (51) 51
neoplasms. tumors. oncology. including cancer and carcinogens (49) 49
antibodies, monoclonal - therapeutic use (48) 48
immune-related response (48) 48
animals (47) 47
blockade (47) 47
management (47) 47
research (47) 47
safety (46) 46
anti-pd-1 (42) 42
pharmacology & pharmacy (42) 42
apoptosis (41) 41
immune checkpoint (41) 41
programmed cell death 1 receptor - antagonists & inhibitors (41) 41
lymphocytes (40) 40
lung neoplasms - drug therapy (39) 39
antineoplastic agents - adverse effects (38) 38
drug therapy (38) 38
immunotherapy - methods (38) 38
melanoma - drug therapy (38) 38
tumors (38) 38
survival (37) 37
antibodies (35) 35
immune related adverse events (35) 35
immunotherapy - adverse effects (34) 34
usage (34) 34
lung cancer, non-small cell (33) 33
adult (32) 32
antigens (32) 32
clinical trials (32) 32
ctla-4 (32) 32
medicine & public health (32) 32
non-small cell lung cancer (32) 32
aged, 80 and over (31) 31
autoimmunity (31) 31
review (31) 31
cell death (30) 30
treatment outcome (30) 30
antineoplastic agents - therapeutic use (29) 29
immune response (29) 29
immune system (29) 29
respiratory system (29) 29
toxicities (29) 29
antibody (28) 28
development and progression (28) 28
antineoplastic agents, immunological - adverse effects (27) 27
solid tumors (27) 27
colitis (26) 26
immune‐related adverse events (26) 26
monoclonal antibodies (26) 26
biomarkers (25) 25
carcinoma, non-small-cell lung - drug therapy (25) 25
checkpoint inhibitor (25) 25
cytotoxicity (25) 25
expression (25) 25
hepatitis (25) 25
immunoglobulins (25) 25
inflammatory bowel disease (25) 25
t cells (25) 25
cancer immunotherapy (24) 24
corticosteroids (24) 24
multicenter (24) 24
patient (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Hematology/Oncology Clinics of North America, ISSN 0889-8588, 2019, Volume 33, Issue 2, pp. 275 - 275
The development of immunotherapy to target cancer has led to improved treatment of many types of malignancy. The immune checkpoint inhibitors are a class of... 
Immune checkpoint inhibitors | Immune-related adverse events | Toxicity | Immunotherapy | ANTIBODY | STAGE-III | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | NIVOLUMAB | BLOCKADE | HEMATOLOGY | PD-1 | ADVERSE EVENTS | IPILIMUMAB
Journal Article
by Puzanov, I and Diab, A and Abdallah, K and Bingham, C.O and Brogdon, C and Dadu, R and Hamad, L and Kim, S and Lacouture, M.E and LeBoeuf, N.R and Lenihan, D and Onofrei, C and Shannon, V and Sharma, R and Silk, A.W and Skondra, D and Suarez-Almazor, M.E and Wang, Y and Wiley, K and Kaufman, H.L and Ernstoff, M.S and Anderson, Jeff and Lehman, Kimberly and Reshef, Dan and Saylors, Ann and Turner, Michelle and Waxman, Ian and Arrindell, Deborah and Andrews, Stephanie and Ballesteros, Joan and Boyer, Janie and Cotarla, Ion and Dawson, Michelle and Goswami, Trishna and Hayreh, Vinny and Holmes, William and Rasheed, Zeshaan and Sarkeshik, Makan and Schreiber, Judy and Shafer-Weaver, Kim and Chen, Daniel and Ley-Acosta, Sergio and Chonzi, David and Go, William and Cunha, Renato and Gulley, James L and Wood, Lauren and Davies, Marianne and Dicker, Adam and Eifler, Lisa and Gregory, Nancy and Ferguson, Andrew and Ferlini, Cristiano and Frankel, Stanley and Gochett, Celestine and Goldberg, Jenna and Patel, Kiran and Wariabharaj, Darshan and Goncalves, Priscila and Helie, Nicole and Hsu, Jer-Yuan and Ibrahim, Ramy and Larocca, Cecilia and Lambotte, Olivier and Luke, Jason and McClure, Joan and Michelon, Elisabete and Nakamura, Mary and Piperdi, Bilal and Riemer, Joanne and Robert, Caroline and Sharfman, William and Sharon, Elad and Sherry, Richard and Simonson, Cyndy and Thomas, Cherry and Trehu, Elizabeth and Thompson, John A and Tresnan, Dina and Zhang, Lin and Zheng, Pan and Soc Immunotherapy Canc Toxicity M and Society for Immunotherapy of Cancer Toxicity Management Working Group and on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2017, Volume 5, Issue 1, pp. 95 - 28
Journal Article
Journal Article
Current Oncology Reports, ISSN 1523-3790, 9/2018, Volume 20, Issue 9, pp. 1 - 12
Journal Article
Surgical oncology clinics of North America, 07/2019, Volume 28, Issue 3, p. 387
Immune checkpoint inhibitors (ICIs) are therapeutic antibodies that target regulatory molecules on T cells and represent the most widely used FDA-approved... 
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Journal of Pain and Symptom Management, ISSN 0885-3924, 09/2018, Volume 56, Issue 3, pp. 460 - 472
Journal Article
Urologic Oncology: Seminars and Original Investigations, ISSN 1078-1439, 12/2017, Volume 35, Issue 12, pp. 701 - 707
With the recent approval of 5 PD-1/PD-L1 inhibitors for a number of malignancies, PD-1 axis inhibition is drastically changing the treatment landscape of... 
Pembrolizumab | Immune-related adverse events | Treatment | Durvalumab | Nivolumab | Avelumab | PD-L1 inhibitor | PD-1 inhibitor | Management | Atezolizumab | ADVANCED CANCER | MULTICENTER | OPEN-LABEL | DOCETAXEL | IMMUNE | ONCOLOGY | ADVANCED MELANOMA | NIVOLUMAB MONOTHERAPY | UROLOGY & NEPHROLOGY | ADVERSE EVENTS | CELL-CARCINOMA | IPILIMUMAB | Immunotherapy - methods | Nephritis - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neurodegenerative Diseases - drug therapy | Hepatitis - drug therapy | Neoplasms - therapy | Exanthema - chemically induced | Pneumonia - chemically induced | Colitis - chemically induced | Nephritis - chemically induced | Colitis - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Hepatitis - etiology | Antibodies, Monoclonal, Humanized - therapeutic use | Programmed Cell Death 1 Receptor - metabolism | Exanthema - drug therapy | Immunotherapy - adverse effects | B7-H1 Antigen - metabolism | B7-H1 Antigen - antagonists & inhibitors | Mycophenolic Acid - therapeutic use | Neurodegenerative Diseases - chemically induced | Pneumonia - drug therapy | Neoplasms - immunology | Neoplasms - pathology | Complications and side effects | Hepatitis | Pneumonia | Bacterial pneumonia | Analysis | Immunotherapy | Mortality | Colitis | Index Medicus
Journal Article